China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in a Phase I clinical trial of IBI363, an in-house developed PD-1/IL-2 bispecific antibody (BsAb) fusion protein, in Australia. The trial will evaluate the safety, tolerability, and preliminary efficacy of IBI363 in patients with advanced solid tumors or lymphoma.
Trial Details
The open-label, multi-center study aims to determine the recommended Phase II dose (RP2D) of IBI363. The drug is designed to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, enhancing the targeting and activation of tumor-specific T cells.
Drug Profile
IBI363, a potential first-in-class candidate, combines PD-1 blockade with selective IL-2 delivery. Preclinical models have shown promising anti-tumor activity, particularly in PD-1 resistant and metastatic settings, with a favorable safety profile.
Strategic Outlook
Innovent plans to leverage the trial data to advance IBI363 globally, targeting unmet needs in oncology. The company’s pipeline includes multiple innovative therapies, with a focus on immuno-oncology and autoimmune diseases.-Fineline Info & Tech
